1993P A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option

Saved in:

Bibliographic Details
Published in	Annals of oncology Vol. 35; p. S1153
Main Authors	D'Souza, A.A., Mar, N., Parikh, R., Parikh, M., Arora, M., Hinton, S., Lyou, Y.M., Ohr, J., Peracha, S., Sadeghi, S., Sulecki, M., Thomas, R.A., Villalona-Calero, M., Lara, P.N., Sharon, E., Krailo, M., Quinn, D.I.
Format	Journal Article
Language	English
Published	Elsevier Ltd 01.09.2024
Online Access	Get full text

Loading…

More Information
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2024.08.2079